🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multi-cancer biomarker. Accurate, fast and cheap ($3) assay detected this endogenous retroviral protein ORF1p in blood of patients with a variety of cancers: Ovarian, esophageal, CRC, etc. aacrjournals.org/cancerdiscover…

Congrats Martin. This is an excellent work. Hope we can use this test in the clinic someday. Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker aacrjournals.org/cancerdiscover…

#OnlineFirst: Sequential #chemoimmunotherapy in #gastriccancer, by Minae An, Arnav Mehta, Byung Hoon Min, You Jeong Heo, Seung Tae Kim, Sam Klempner, Jeeyun Lee MD et al. bit.ly/3wbc76g Mass General Cancer Center @Broadinstitute #SamsungMedicalCenter SU2Cscience

🌟Join us at KSMO Annual Meeting🌟 Stay connected with Korean oncologists at COEX, Seoul, Korea & online on September 26-27! Highlights include annual joint sessions of ASCO ESMO - Eur. Oncology 日本臨床腫瘍学会（JSMO） Register now!👉bit.ly/3MzP3mI

#ESMO24 T-DXd monotherapy and combinations in pts with advanced HER2+ esophageal, gastric or GEJ adenocarcinoma: DESTINY-Gastric03 Toxicity is high at 6.4 mg, while the follow-up period for 5.4 mg is quite short. The 5.4 mg dose shows promise. Longer follow-up is needed

Niche 2 after two doses of nivolumab and one dose of ipi and surgery. 100% of patients with MSI high colon cancer relapse free at 3 years. Arguably preop IO should be a new care standard in MSI high colon cancer.

Pembrolizumab + CAPOX /bevacizumab in MSS CRC and a high immune infiltrate #ESMO24 🔎POCHI trial 👉ORR 74%, DRC 100%, 5 CR 👉12-mo PFS rate 51% 👉2-yr OS rate 80% 👉AEs ≥3 70% 🧐IMMUNOSCORE and TuLIS score (18% of pts) to select ICI in mCRC? ESMO - Eur. Oncology #ESMOAmbassadors

Extremely fortunate 💜to have the best mentor Eileen M O’Reilly and mentee Catherine O’Connor A strong teamwork at Memorial Sloan Kettering Cancer Center We are sharing each other's slides in transatlantic presentations at #AACRpan24 and #ESMO24 A lot of active research👨‍🔬MSKCC Center for Pancreatic Cancer Research Congrats! Keynote 📢speech

Pleased to share final survival results of two phase 3 of zolbetuximab NEJM  which reinforce zolbetuxumab plus chemo as effective treatment option, though still need better treatment. More agents will be coming for CLDN18.2+ GC ESMO - Eur. Oncology OncoAlert #ESMO24 nejm.org/doi/full/10.10…

I'm excited to see this early data at #ESMO24 on AMG 193 for my patients with pancreas, biliary & oesophageal cancer 👏👏 MTAP deletion is a new target for hard to treat cancers annalsofoncology.org/article/S0923-… #Presidential ESMO - Eur. Oncology

Andres Cervantes discussing neoadjuvant treatment of rectal cancers KSMO International ESMO - Eur. Oncology joint session in #Seoul.

🔥#KSMO2024 #JSMO2025 booth 🙌We welcome 🇰🇷 and 🌎🌍participants to Kobe🇯🇵 🗓March 6th to 8th, 225 ✔️English as Official language ✔️Joint symposium with ASCO, ESMO - Eur. Oncology and more KSMO International 日本臨床腫瘍学会（JSMO） #LCSM OncoAlert

Thank you for ASCO sessions especially Lynn Schuchter. ASCO. We see stage iv everyday but still hard to judge when to start palliative care for each patient. KSMO International

I’m deeply honored to receive this award (future leader award) for my postdoctoral work. aacrjournals.org/cancerdiscover… aacrjournals.org/cancerdiscover… I am also incredibly grateful to my mentor Jeeyun Lee MD and my colleagues who guided and worked alongside me.

Great discussion at #esmo2024 on leveraging new technologies for optimized treatment in GI cancer. Thanks to #anminae for all the analysis you have done for our patients.

Claudin 18.2 and Fgfr2b in GC as first-line tx. Thanks to #weipengyong #hisatokaeakami, Dr. Kyoung Mee Kim #esmo2024 for insightful panel discussions. Exciting time to treat GI cancers with more tx options yet to come. #anminae

Adding some spatial omics to HER2+ gastric cancer. Determinants of Response to Sequential Pembrolizumab with Trastuzumab Plus Platinum/5FU in HER2-positive Gastric Cancer: A Phase II Trial aacrjournals.org/clincancerres/… Jeeyun Lee MD Minae An Arnav Mehta Clinical Cancer Research

Tremelimumab & durvalumab as neoadjuvant or non-operative management strategy for MSI GC/GEJ cancer Annals of Oncology doi.org/10.1016/j.anno… 🔎 INFINITY study by GONO 👉17 pts > 13 cCR > non-operative management > only 1 recurrence 🧐W&W in GC/GEC ... exciting ESMO - Eur. Oncology

Stay Connected with #KSMO_INTL at #ASCO25 We're excited to meet Korea–US oncologists at this special networking event!🥂 Let’s connect🤝, collaborate🧩, and celebrate together!🎉 👉Learn more bit.ly/4jj3s4R

linkedin.com/posts/jeeyun-l…